[144] Zoom Communications, Inc. SEC Filing

Rhea-AI Filing Summary

T2 Biosystems, Inc. (TTOO) has been formally notified of its removal from the Nasdaq Stock Market. Nasdaq filed a Form 25 on 2025-07-10, certifying that it meets all regulatory requirements to strike the company’s common stock from listing and registration under Section 12(b) of the Securities Exchange Act of 1934.

The filing indicates that either: (i) Nasdaq initiated the action under Rule 12d2-2(a), or (ii) the company voluntarily withdrew under Rule 12d2-2(c); the specific box selected is not shown, but Nasdaq confirms procedural compliance. Once the Form 25 becomes effective—generally 10 days after filing—T2 Biosystems’ shares will no longer trade on Nasdaq, and registration under Section 12(b) will be withdrawn 90 days thereafter unless the SEC objects.

Key implications for investors:

• Shares will be delisted from Nasdaq; trading may move to over-the-counter markets with reduced liquidity and visibility.
• Index inclusion and institutional ownership could decline due to listing requirements.
• The company will still be subject to certain SEC reporting obligations unless it files to terminate them separately.

Positive

• None.

Negative

• Nasdaq delisting via Form 25 removes TTOO shares from a major exchange, cutting liquidity and potentially signaling financial distress.

Insights

Financial Analyst

TL;DR: Nasdaq filed Form 25 to delist TTOO; materially negative due to liquidity and reputational hit.

Delisting from a major exchange is typically a strong negative signal. It can stem from non-compliance with listing standards (price, market cap, or reporting) or a voluntary move, but either path limits share liquidity, narrows investor base, and may trigger covenant or index removal clauses. OTC trading often results in wider bid-ask spreads and higher volatility. Unless management discloses a strategic rationale, the action suggests financial or operational stress. Investors should reassess valuation assumptions, factor in higher cost of capital, and monitor any subsequent SEC filings for deregistration or restructuring plans.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	7661	593727.50	302547624	07/10/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/09/2025	Restricted Stock	ISSUER			7661	07/09/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
VELCHAMY SANKARLINGAM 55 Almaden Boulevard, 6th Floor San Jose CA 95113	Common	06/10/2025	2595	208274.70
VELCHAMY SANKARLINGAM 55 Almaden Boulevard, 6th Floor San Jose CA 95113	Common	04/15/2025	7661	550902.51
VELCHAMY SANKARLINGAM 55 Almaden Boulevard, 6th Floor San Jose CA 95113	Common	04/15/2025	4178	300439.98

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

Why did Nasdaq file Form 25 for T2 Biosystems (TTOO)?

Nasdaq certified compliance with SEC Rule 12d2-2 to remove TTOO common stock from listing and registration under Section 12(b).

When will TTOO shares be delisted from Nasdaq?

The Form 25 generally becomes effective 10 days after the 2025-07-10 filing date, at which point Nasdaq trading ceases.

Will T2 Biosystems stop filing SEC reports after delisting?

Delisting under Form 25 does not automatically terminate reporting; additional filings are required for full deregistration.

Where can investors trade TTOO after delisting?

Shares typically migrate to over-the-counter venues, which offer lower liquidity and less visibility than Nasdaq.

What risks follow a Nasdaq delisting for TTOO shareholders?

Key risks include reduced liquidity, wider bid-ask spreads, loss of index inclusion, and potential covenant breaches.